Filing Details
- Accession Number:
- 0001562180-24-000325
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-08 06:03:09
- Reporting Period:
- 2024-01-03
- Accepted Time:
- 2024-01-08 06:03:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1560241 | G1 Therapeutics Inc. | GTHX | Pharmaceutical Preparations (2834) | 263648180 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1877793 | Andrew Perry | 700 Park Offices Drive, Suite 200 Research Triangle Park NC 27709 | Chief Commercial Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-01-03 | 33,570 | $0.00 | 89,515 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2024-01-03 | 379 | $3.12 | 89,136 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-01-03 | 2,034 | $3.12 | 87,102 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Acquisiton | 2024-01-03 | 67,050 | $0.00 | 67,050 | $2.97 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 67,050 | 2034-01-03 | No | 4 | A | Direct |
Footnotes
- Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2025 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
- Each RSU represents a contingent right to receive one share of Issuer common stock.
- Represents (i) 1,095 shares of common stock; (ii) 3,750 RSUs from award granted on January 3, 2022; (iii) 16,100 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 33,570 RSUs from award granted on January 3, 2024.
- The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a sell-to-cover transaction and do not represent discretionary transactions by the Reporting Person.
- The price represents the weighted average price with a low of $3.08 and a high of $3.16. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Represents (i) 1,466 shares of common stock; (ii) 3,000 RSUs from award granted on January 3, 2022; (iii) 16,100 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 33,570 RSUs from award granted on January 3, 2024.
- Represents (i) 3,457 shares of common stock; (ii) 3,000 RSUs from award granted on January 3, 2022; (iii) 12,075 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 33,570 RSUs from award granted on January 3, 2024.
- The shares underlying this option vest as to 25% of the shares on January 3, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
Billionaire Hedge Funds
